A 76-year-old man with metastatic castration-resistant prostate carcinoma progressing with antiandrogen and taxane therapy was treated with lutetium 177 prostate-specific membrane antigen (PSMA)-617 and showed marked biochemical and imaging response, with improvement in clinical status and osseous pain. A summary of nuclear medicine theranostics with emphasis on PSMA targeting agents is presented.

中文翻译：

---

转移性去势抵抗性前列腺癌患者的 177Lu-前列腺特异性膜抗原放射配体治疗。

一名患有转移性去势抵抗性前列腺癌的 76 岁男性在接受抗雄激素和紫杉烷治疗后进展，接受了镥 177 前列腺特异性膜抗原 (PSMA)-617 治疗，并显示出显着的生化和影像学反应，临床状态和骨质改善疼痛。介绍了以 PSMA 靶向剂为重点的核医学治疗诊断学摘要。